212 related articles for article (PubMed ID: 18464784)
1. Retinal anti-angiogenesis by a new route.
Bicknell R
Nat Biotechnol; 2008 May; 26(5):528-9. PubMed ID: 18464784
[No Abstract] [Full Text] [Related]
2. Treatment of retinal diseases with VEGF antagonists.
Schlingemann RO; Witmer AN
Prog Brain Res; 2009; 175():253-67. PubMed ID: 19660661
[TBL] [Abstract][Full Text] [Related]
3. Modulating the tumor microenvironment to improve radiotherapy.
Maity A
Retina; 2009 Jun; 29(6 Suppl):S32-3. PubMed ID: 19553796
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor agents for pediatric retinal diseases.
Wykoff CC; Houston SK; Berrocal AM
Int Ophthalmol Clin; 2011; 51(1):185-99. PubMed ID: 21139484
[No Abstract] [Full Text] [Related]
5. Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia.
Kim YH; Chung IY; Choi MY; Kim YS; Lee JH; Park CH; Kang SS; Roh GS; Choi WS; Yoo JM; Cho GJ
Neurobiol Dis; 2007 Jun; 26(3):569-76. PubMed ID: 17434742
[TBL] [Abstract][Full Text] [Related]
6. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
7. VEGF targeted therapy in acute myeloid leukemia.
Rodriguez-Ariza A; Lopez-Pedrera C; Aranda E; Barbarroja N
Crit Rev Oncol Hematol; 2011 Nov; 80(2):241-56. PubMed ID: 21035354
[TBL] [Abstract][Full Text] [Related]
8. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
[No Abstract] [Full Text] [Related]
9. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
Ellis LM
J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
[No Abstract] [Full Text] [Related]
10. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
11. [Molecular structure and abnormal expression of angiopoietin-2 and antiangiogenic targeting therapy of hepatocelluar carcinoma].
GU WJ; YAO DF
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):398-400. PubMed ID: 19497214
[No Abstract] [Full Text] [Related]
12. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.
Fallah A; Sadeghinia A; Kahroba H; Samadi A; Heidari HR; Bradaran B; Zeinali S; Molavi O
Biomed Pharmacother; 2019 Feb; 110():775-785. PubMed ID: 30554116
[TBL] [Abstract][Full Text] [Related]
13. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
14. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
[TBL] [Abstract][Full Text] [Related]
15. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
Kepes JJ
Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
[No Abstract] [Full Text] [Related]
16. [Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].
Khalaim AV; Stoliarenko GE
Vestn Oftalmol; 2007; 123(5):54-6, preceding 56. PubMed ID: 18078062
[No Abstract] [Full Text] [Related]
17. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Roy V; Perez EA
Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
[TBL] [Abstract][Full Text] [Related]
19. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Ellis LM; Hicklin DJ
Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor.
Ferrara N
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):789-91. PubMed ID: 19164810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
